183 related articles for article (PubMed ID: 20698928)
1. Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide.
Tirkkonen T; Heikkilä P; Huupponen R; Laine K
J Intern Med; 2010 Oct; 268(4):359-66. PubMed ID: 20698928
[TBL] [Abstract][Full Text] [Related]
2. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Diabetes Care; 2010 Jun; 33(6):1224-9. PubMed ID: 20215447
[TBL] [Abstract][Full Text] [Related]
3. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Diabetes Obes Metab; 2012 Sep; 14(9):803-9. PubMed ID: 22486923
[TBL] [Abstract][Full Text] [Related]
4. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
[TBL] [Abstract][Full Text] [Related]
5. Effects of glimepiride and glibenclamide on carotid atherosclerosis in type 2 diabetic patients.
Katakami N; Kaneto H; Matsuhisa M; Shimomura I; Yamasaki Y
Diabetes Res Clin Pract; 2011 Apr; 92(1):e20-2. PubMed ID: 21257219
[TBL] [Abstract][Full Text] [Related]
6. [Clinical efficacy of a Minidiab preparation (glipizide) in an acute experiment].
Borisova AM; Taneva T; Koev D; Georgieva R
Vutr Boles; 1988; 27(2):85-9. PubMed ID: 3137730
[TBL] [Abstract][Full Text] [Related]
7. Glipizide and glyburide.
Kure J
N C Med J; 1986 Mar; 47(3):149-53. PubMed ID: 3083269
[No Abstract] [Full Text] [Related]
8. The new oral antidiabetic drugs.
Moss JM; Delawter DE
Am Fam Physician; 1984 Nov; 30(5):119-21. PubMed ID: 6437197
[No Abstract] [Full Text] [Related]
9. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH
Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710
[TBL] [Abstract][Full Text] [Related]
10. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide.
Massi-Benedetti M; Herz M; Pfeiffer C
Horm Metab Res; 1996 Sep; 28(9):451-5. PubMed ID: 8911982
[TBL] [Abstract][Full Text] [Related]
11. Probable hypoglycemic adverse drug reaction associated with prickly pear cactus, glipizide, and metformin in a patient with type 2 diabetes mellitus.
Sobieraj DM; Freyer CW
Ann Pharmacother; 2010; 44(7-8):1334-7. PubMed ID: 20516361
[TBL] [Abstract][Full Text] [Related]
12. Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure.
Andersson C; Gislason GH; Jørgensen CH; Hansen PR; Vaag A; Sørensen R; Mérie C; Olesen JB; Weeke P; Schmiegelow M; Norgaard ML; Køber L; Torp-Pedersen C
Diabetes Res Clin Pract; 2011 Oct; 94(1):119-25. PubMed ID: 21831467
[TBL] [Abstract][Full Text] [Related]
13. Hypoglycemia in hospitalized patients treated with sulfonylureas.
Deusenberry CM; Coley KC; Korytkowski MT; Donihi AC
Pharmacotherapy; 2012 Jul; 32(7):613-7. PubMed ID: 22570146
[TBL] [Abstract][Full Text] [Related]
14. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
Niemi M; Cascorbi I; Timm R; Kroemer HK; Neuvonen PJ; Kivistö KT
Clin Pharmacol Ther; 2002 Sep; 72(3):326-32. PubMed ID: 12235454
[TBL] [Abstract][Full Text] [Related]
15. Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study.
Herman WH; Dirani RG; Horblyuk R; O'Neill MC; Kravitz B; Heise MA; Bakst A; Freed MI;
Am J Manag Care; 2005 Apr; 11(4):273-8. PubMed ID: 15839187
[TBL] [Abstract][Full Text] [Related]
16. Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study.
Sadikot SM; Mogensen CE
Diabetes Res Clin Pract; 2008 Dec; 82(3):391-5. PubMed ID: 18945509
[TBL] [Abstract][Full Text] [Related]
17. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.
Ragia G; Petridis I; Tavridou A; Christakidis D; Manolopoulos VG
Pharmacogenomics; 2009 Nov; 10(11):1781-7. PubMed ID: 19891554
[TBL] [Abstract][Full Text] [Related]
18. Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents.
Prendergast BD
Clin Pharm; 1984; 3(5):473-85. PubMed ID: 6435940
[TBL] [Abstract][Full Text] [Related]
19. An overview of the safety and tolerance of glimepiride.
Schneider J
Horm Metab Res; 1996 Sep; 28(9):413-8. PubMed ID: 8911975
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus.
González-Ortiz M; Guerrero-Romero JF; Violante-Ortiz R; Wacher-Rodarte N; Martínez-Abundis E; Aguilar-Salinas C; Islas-Andrade S; Arechavaleta-Granell R; González-Canudas J; Rodríguez-Morán M; Zavala-Suárez E; Ramos-Zavala MG; Metha R; Revilla-Monsalve C; Beltrán-Jaramillo TJ
J Diabetes Complications; 2009; 23(6):376-9. PubMed ID: 18849173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]